Advancing Alzheimer's Innovation: Patient Advocacy, Caregiver Support and Health Care System Impact
As researchers work towards disease modifying therapies, we must also press ahead on initiatives that prepare society for the proper care of Alzheimer’s sufferers — and caregivers. A small number of nations — France, the United Kingdom and Australia among them — have created comprehensive national policies to manage Alzheimer’s disease and to offer compassionate care to its sufferers. Employers are also being impacted by loss of productivity and responding by increasing their support for employees who are providing care to loved ones with Alzheimer’s and other age-related chronic conditions. Private sector innovation is also starting to respond to the growing need to help individuals remain independent for as long as possible. This forum will focus on best practices in care delivery to support patients and caregivers, whether in institutions or at home.
Learning Objective(s): Describe opportunities to bridge the regulatory and industry gap; Identify how industry and other stakeholders increase faster clinical trial enrollment and enhance data collection; Discuss examples where patients/industry/regulatory collaborated, thus advancing therapies.
Chair(s): Robert Feeney, MBA Senior Director, Evidence-Based Reimbursement Sanofi, United States
Presentation(s) & Speaker(s): Cynthia Bens VP, Public Policy, Alliance for Aging Research, Accelerate Cure/Treatments for Alzheimer's Disease (ACT-AD), United States; Francesca Cerreta, PharmD,MPharm,MS Scientific Administrator European Medicines Agency, European Union, United Kingdom; Drew Holzapfel, MBA Managing Director High Lantern Group , United States.